William E. Ford elected Chair of The Rockefeller University Board
Ford succeeds Russell L. Carson, who is retiring after leading the Board for the past 13 years.
Rockefeller tops global university ranking in measures of research excellence and patents
The university ranks first in two major categories in a survey of more than 1600 institutions.
A. James Hudspeth to receive Kavli Prize in Neuroscience
Hudspeth is receiving the honor for pioneering work on the molecular and neural mechanisms of hearing.
Gaby Maimon and Luciano Marraffini are named HHMI investigators
Maimon, who studies cognition and decision-making, and Marraffini, who studies the bacterial defense system CRISPR-Cas, are among 19 scientists nationwide to receive this designation.
Sohail Tavazoie promoted to professor
Sohail Tavazoie, a physician-scientist who studies the genes that regulate a tumor’s ability to metastasize, has been promoted to professor.
Rockefeller takes first place in global ranking of scientific impact
Out of over 900 universities from 55 different countries, Rockefeller tops a survey measuring the impact of university research publications, scoring the highest percentage of frequently cited scientific publications.
Small molecule from Kapoor lab is accepted as first Bridge Medicines drug candidate
A chemical inhibitor targeting basal cell carcinoma, originating from Tarun Kapoor’s lab, is graduating from the Tri-Institutional Therapeutics Discovery Institute into Bridge Medicines.
Astrophysicist Kip Thorne to receive Rockefeller’s 2018 science writing prize
Thorne is recognized for his deft explanations that have drawn readers into the space-, time-, and mind-bending realm of Einstein’s ideas. The prize, which honors scientists as inspirational authors, will be presented on April 17.
Günter Blobel, a Nobel laureate who redefined cell biology, has died
Günter Blobel, a Nobel Prize-winning Rockefeller biologist who discovered the mechanisms by which proteins are targeted for delivery to specific locations within cells, died February 18 at 81.
Proof of principle: Tri-I TDI drug candidates “graduate” to next phase of development
As inaugural Sanders Director Dr. Michael Foley is set to depart the Tri-Institutional Therapeutics Discovery Institute later this year, two projects from a portfolio of 57 that the Tri-I TDI has supported are now ready for the next phase of therapeutic development—a phase intended to lead to investigational new drugs.
